Centre de Regulaciˇ Gen˛mica

Fundacio Privada Centre de Regulacio Genomica

Fundacio Privada Centre de Regulacio Genomica
Doctor Aiguader No 88
8003 Barcelona
Spain

http://www.crg.es

Principal Investigator

Prof. Xavier Estivill

Prof. Xavier Estivill

Phone +34-93-316-0100

Contact

Institute Presentation

The Centre for Genomic Regulation (CRG, http://www.crg.es) is an interdisciplinary biomedical research institute located in the Barcelona Biomedical Research Park (PRBB, http://www.prbb.es), a cluster for biomedical research in southern Europe, which includes several other biomedical research institutions and more than 1,000 researchers. Research at the CRG is organised into six programs (Systems Biology, Bioinformatics and Genomics, Gene regulation, Cell and Developmental Biology, Differentiation and Cancer, and Genes and Disease) led by outstanding international program coordinators and international young group leader scientists. Currently the institute hosts 30 research groups with around 300 researchers and has five main central facilities which have the latest instrumentation: Light microscope facility, Proteomics, Genomics and Ultrasequencing, High throughput screening, and FACS. In addition, scientists at the CRG have access to the PRBB animal house and PET for human and murine research. The proximity with the Hospital del Mar, located in the PRBB, creates opportunities for interactions between basic and clinical sciences, thus promoting translational research. Xavier Estivill is the coordinator of the Genes and Diseases Programme, which comprises 5 research groups (Murine Models of Disease, Neurobehavioral Analysis, Genetic Causes of Disease, Gene therapy, and Gene Function). The Genes and Disease programme is supported by the Spanish Ministry of Health (and the Catalan Government (Generalitat de Catalunya) and has contributed to the ENCODE project and to the structural genome variation project.

The Genes and Disease Programme (Xavier Estivill) develops projects of gene identification, experimental models of human diseases, behaviour in models of diseases, and gene transfer applications for the treatment of human disorders. The group is involved in the study of structural variability (mainly copy number variation, CNV) of the human genome and predisposition to disease.

The CRG Genomics Core Facility (CRG-GCF) has three high-priority technological platforms: 1) Expression, 2) High-throughput genotyping, and 3) Next-generation sequencing. GCF provides services to CRG and external researchers for gene expression profiling, ChIP-on-chip, arrayCGH, SNP analysis, methylation profiling, DNA extraction and DNA sequencing. The CRG-GCF is equipped with state-of-the-art instruments including four robotic liquid handlers and sensitive-analysis equipment for processing high-throughput, low volume, automated genomic technologies.

The Genotyping Unit at the CRG-GCF is one of the three nodes of the National Centre of Genotyping (CeGen, http://www.cegen.org). CeGen was created in 2003 by ôFundaciˇn Genoma Espa˝aö, with the mission of providing support to scientists in their genotyping projects in every aspect of research, from planning, DNA extraction, genotyping, data interpretation, through to statistical analysis. Its current capacity includes: 1) one BeadScanner and associated robotic equipment, which allows for the weekly processing of 540 samples through GoldenGate genotyping/DNA Methylation, and 48 chips through Infinium II (up to one billion genotypes per year); 2) one 3730xl capillary instrument that enables to genotype by SNPlex 12 384well plates per week (200 000 samples and nine million genotypes per year); and 3) one Chemagen system for automated sample preparation that can extract DNA from 10 000 large volume blood samples per year. Future additions include an autoloader for the BeadScanner that will greatly increase throughput of sample processing and the BeadXpress scanner that uses the Veracode technology to genotype up to 384 custom SNPs simultaneously with lower costs per assay. A LIMS has been implemented to manage and track every sample with their associated results and to provide the laboratory with capabilities for electronic worksheet generation and instrument and robotic integration. The CRG-GCF has already acquired two next-generation sequencers: one Genome Analyzer (Solexa/Illumina) and one GS-FLX (454/Roche). CRG-GCF is currently providing de novo sequencing and resequencing, expression profiling, microRNA discovery and profiling and ChIP-seq applications with the Solexa instrument. The IT infrastructure includes a secure client-server network with a central LINUX HP Proliant DL580 G4 server connected via FC to a SAN containing 15TB of raw storage.

CRG will be involved in networking activities (WP2 and WP4), transnational access (focussing on genotyping and CNV analysis), and in RTD (WP11), concentrating on data analysis software development for the analysis of CNVs by sequencing and genotyping methods as well as analysis of non-coding RNAs.